SpaceX podría superar los USD $2 billones en su debut, apuntan traders de Polymarket Ivar AI

The Times of India

US stocks: SpaceX to make historic listing on Nasdaq on Friday that could make Elon Musk a trillionaire

BusinessLine

SpaceX IPO pushes Elon Musk’s net worth past $1 trillion

KQED

SpaceX Blasts Off With a Record-Breaking $75 Billion IPO

CBS News

OpenAI says it filed confidential IPO as it positions itself for AI arms race

BBC News

Live: US striking Iran in response to downing of helicopter, military says

CoinDesk

Elon Musk's SpaceX prices shares at $135, raising $75 billion in largest-ever IPO

Business Insider

SpaceX Live Updates: Elon Musk's Rocket Company Set to Price Hyped IPO

CBS News

How to buy SpaceX shares as its blockbuster IPO readies for liftoff

Expresso.pt

BCE aumenta taxa diretora pela primeira vez em quase três anos para os 2,25%

Www.abc.es

¿Podrá el mercado bursátil digerir a Anthropic, SpaceX y OpenAI?

Diariobitcoin.com

Audiera ($BEAT) desafía la gravedad: ¿burbuja o nuevo paradigma cripto?

Www.abc.es

El BCE planta cara a la inflación y sube los tipos por primera vez en casi tres años hasta el 2,25%

Nacion.com

Estados Unidos lanza nuevos ataques contra Irán

The Daily Caller

China Pours More Fuel On The AI Arms Race Fire

The Conversation Africa

SpaceX raised $75B in record IPO – here’s why insiders like Elon Musk are much likelier than public stock buyers to get rocket-powered returns these days

Forbes

Investor Demand For SpaceX IPO Tops $250 Billion, Report Says

Fortune

ChatGPT maker OpenAI confidentially files for IPO, a week after Anthropic

Eldiario.es

La industria del deporte ya mueve más de dos billones de euros en el mundo y supera al PIB de España

Yahoo Entertainment

美伊衝突再掀地緣風險美股跌逾1%科技股重挫

Olhardigital.com.br

SpaceX define ação a US$ 135 e bate recorde histórico de IPO

$Cellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en essai pivot pour les patients atteints de LLA-B en rechute ou réfractaire$

GlobeNewswire

Cellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en essai pivot pour les patients atteints de LLA-B en rechute ou réfractaire